CN116966191A - Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution - Google Patents

Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution Download PDF

Info

Publication number
CN116966191A
CN116966191A CN202210425667.0A CN202210425667A CN116966191A CN 116966191 A CN116966191 A CN 116966191A CN 202210425667 A CN202210425667 A CN 202210425667A CN 116966191 A CN116966191 A CN 116966191A
Authority
CN
China
Prior art keywords
gly
leu
thr
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210425667.0A
Other languages
Chinese (zh)
Inventor
於邱黎阳
陈柳青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Institute of Advanced Technology of CAS
Original Assignee
Shenzhen Institute of Advanced Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Advanced Technology of CAS filed Critical Shenzhen Institute of Advanced Technology of CAS
Priority to CN202210425667.0A priority Critical patent/CN116966191A/en
Priority to PCT/CN2022/138175 priority patent/WO2023202099A1/en
Publication of CN116966191A publication Critical patent/CN116966191A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention discloses a method for regulating and controlling NAD (NAD) in cells by glycerophosphorylcholine + Application of glycerophosphorylcholine in level and distribution capable of specifically regulating cell nucleus and mitochondria NAD + Level and distribution which specifically increases nuclear NAD + Level and distribution to reduce mitochondrial NAD + Level and distribution of subcellular NAD-based + Metabolic regulated disease treatment strategies provide pharmaceutical and nutritional intervention approaches.

Description

Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution
Technical Field
The invention belongs to the technical field of biology, and relates to application of a compound, in particular to application of glycerophosphorylcholine in regulation and control of cell Nicotinamide Adenine Dinucleotide (NAD) + ) Horizontal and distributed applications.
Background
Nicotinamide Adenine Dinucleotide (NAD) + ) Has important functions for all organisms: as a coenzyme factor, participate in hundreds of redox reactions; tens of regulatory enzyme molecules such as PARPs and SSubstrates for IRTs; reference is made to atypical RNA-capping modifications. Thus, intracellular NAD + Has important effects on cell metabolism, cell signaling and gene expression regulation. Intracellular NAD + The level changes dynamically in numerous physiological phenomena such as aging, neurodegeneration, kidney injury, obesity, and diabetes. In eukaryotic cells, NAD + Has the characteristic of high compartmentalization, and is widely distributed in cytoplasm, nucleus, mitochondria, endoplasmic reticulum and golgi apparatus. Compartmentalized NAD in living cells + Metabolic status regulates many physiological processes associated with diseases and metabolic disorders, and is an important mechanism for integrating energy metabolism and signal-induced gene transcription. It was found that adipogenic signals rapidly induced cytoplasmic NAD + Expression of the synthase NMNAT-2 and its interaction with the nucleus NAD + Synthetase NMNAT-1 competes for the co-substrate nicotinamide mononucleotide, resulting in nuclear NAD + The level is drastically reduced, leading to the original NAD + Unbalanced space-time distribution and further induces the adipogenic transcription of cells, induces the differentiation of adipocytes, and reverses the nucleus NAD + The decrease can reduce the lipid-forming transcription of the cell. The organelle NAD + The unbalanced process of space-time distribution plays a significant role in lipid cell differentiation and neuroblastoma function regulation, remodelling organelle NAD + The spatiotemporal distribution is expected to play a positive role in regulating adipogenic differentiation and neuroblastoma function. At the same time, it has been found that cytoplasmic NAD + Plays an important role in ovarian cancer by regulating translation and maintaining protein homeostasis. Expression of cytoplasmic NMNAT-2 is highly up-regulated in ovarian cancer, and associated with nuclear NAD + Synthesis competes, resulting in nuclear NAD + Reduced level, NAD + The space-time distribution is unbalanced. At the same time NMNAT-2 can maintain the catalytic activity of mono (ADP-ribosyl) transferase PARP-16, and PARP-16 can make ribosomal protein mono ADP-ribosyl. Downregulation of NMNAT-2 or PARP-16 results in inhibition of mono ADP-ribosylation, increased polysome binding, enhanced translation of specific mRNA, aggregation of related protein products, and reduced growth of ovarian cancer cells. Elucidation of cytoplasmic NMNAT-2 mediated nuclear NAD + Level drop and NAD + The imbalance of the spatial and temporal distribution plays an important role in protein homeostasis and metabolic abnormalities of cancers such as ovarian cancer by regulating PARP-16 activity. In conclusion, due to NAD + The development of NAD in the distribution of mitochondria and nuclei regulating a number of disease-related processes + The organelle specific regulatory molecules have important significance and are promising metabolic drugs and nutritional intervention strategies.
Glycerol phosphorylcholine (L-Alpha-glycerophosphoryl choline, alpha-GPC for short) is composed of choline, glycerol and phosphate, and the structure is shown in FIG. 1. Alpha-GPC naturally exists in human body, is a precursor for synthesizing neurotransmitter acetylcholine, and has important nutrition and health care functions and medical values. Numerous academic studies and clinical trials indicate that Alpha-GPC has the effects of improving cognitive function, resisting hyperlipidemia and protecting blood vessels, and can be used for treating diseases such as alzheimer's disease and schizophrenia. However, there is no Alpha-GPC and NAD + Is a study report of the relationship of (2).
Disclosure of Invention
In order to solve the defects in the prior art, the invention aims to provide the application of glycerophosphorylcholine in regulating and controlling the level and distribution of nicotinamide adenine dinucleotide of cells.
In a first aspect, the invention provides the use of glycerophosphorylcholine for controlling cellular nicotinamide adenine dinucleotide levels and distribution ratios.
Further, the glycerophosphorylcholine is used to regulate the level and distribution of nicotinamide adenine dinucleotide in the subcellular structure of living cells.
Further, the subcellular structure is a nucleus or a mitochondrion.
Further, the glycerophosphorylcholine is used to increase nuclear nicotinamide adenine dinucleotide levels and distribution, and/or decrease mitochondrial nicotinamide adenine dinucleotide levels and distribution.
In a second aspect, the invention provides the use of glycerophosphorylcholine for the preparation of a pharmaceutical composition for the prevention and/or treatment of diseases associated with the regulation of cellular nicotinamide adenine dinucleotide metabolism.
Further, the glycerophosphorylcholine is used for preparing a pharmaceutical composition for preventing and/or treating diseases related to the regulation of subcellular structure nicotinamide adenine dinucleotide metabolism.
Further, the glycerophosphorylcholine is used for preparing a pharmaceutical composition for preventing and/or treating diseases related to the reduction of the level and distribution of the nuclear nicotinamide adenine dinucleotide and/or the increase of the level and distribution of the mitochondrial nicotinamide adenine dinucleotide;
preferably, the cell nicotinamide adenine dinucleotide metabolism regulation-related disease comprises lipid cell differentiation abnormality, mitochondrial energy metabolism disease, and subcellular NAD expression + Alzheimer's disease with unbalanced distribution, pseudohypoxia, etc.
In a third aspect, the invention provides the use of glycerophosphorylcholine for the preparation of a health product, dietary supplement, functional food, medical food or nutritional supplement for regulating and controlling cellular nicotinamide adenine dinucleotide levels and distribution, anti-aging, prolonging cell life, assisting in reducing blood lipid or assisting in reducing blood glucose.
In a fourth aspect, the present invention provides a pharmaceutical formulation for modulating the level and distribution of nicotinamide adenine dinucleotide in a cell, wherein the active ingredient of the pharmaceutical formulation comprises glycerophosphorylcholine;
preferably, the pharmaceutical formulation is for increasing nuclear nicotinamide adenine dinucleotide levels and distribution, and/or decreasing mitochondrial nicotinamide adenine dinucleotide levels and distribution.
In a fifth aspect, the present invention provides a pharmaceutical composition for preventing and/or treating a disease associated with regulation of cellular nicotinamide adenine dinucleotide metabolism, the active ingredient of the pharmaceutical composition comprising glycerophosphorylcholine;
preferably, the pharmaceutical composition is used for preventing and/or treating diseases associated with reduced levels and distribution of nuclear nicotinamide adenine dinucleotide and/or increased levels and distribution of mitochondrial nicotinamide adenine dinucleotide.
In a sixth aspect the present invention provides a health product, dietary supplement, functional food, medical food or nutritional supplement, the ingredients of which include glycerophosphorylcholine;
preferably, the health product, dietary supplement, functional food, medical food or nutritional supplement is used to regulate cellular nicotinamide adenine dinucleotide level and distribution, to resist aging, to extend cellular life, to assist in reducing blood lipid or to assist in reducing blood glucose.
The beneficial effects of the invention are as follows:
the invention reports for the first time that Alpha-GPC can specifically regulate and control cell nucleus and mitochondria NAD + Level and distribution Alpha-GPC can specifically increase nuclear NAD + Level to reduce mitochondrial NAD + Level of subcellular NAD-based + Metabolic regulated disease treatment strategies provide pharmaceutical and nutritional intervention approaches.
Alpha-GPC does not cause any acute, subacute or chronic harm to the human body, and can be used for developing health products, dietary supplements, functional foods, medical foods or nutritional supplements for regulating and controlling the level and distribution of cell nicotinamide adenine dinucleotide, resisting aging, prolonging the life of cells, assisting in reducing blood fat or assisting in reducing blood sugar.
Drawings
FIG. 1 is a schematic diagram of the structure of the compound Alpha-GPC.
FIG. 2 (A) is a schematic diagram showing the operation of the probe NADS2.0 and NADS3.0. (B) The specific expression patterns of the probes NADS2.0 and NADS3.0 for adding nuclear or mitochondrial localization peptides in cells are shown.
FIG. 3 (A) is a graph showing the ratio of luminescence intensities at 515nm and 440nm of HEK 293T cells with mitochondrial specific expression probe NADS2.0 after 24h of combination treatment of Alpha-GPC with different concentrations of FK 866. (B) HEK 293T cells expressing the probe NADS2.0 for nuclei were subjected to a combination treatment of Alpha-GPC and FK866 at different concentrations for 24h, and the ratio of luminous intensities at 515nm and 440nm was plotted. All P values were calculated using unpaired two-tailed Student's t tests: * p <0.05, < p <0.01; * P <0.001; * P <0.0001.
FIG. 4 (A) is a FRET signal micrograph of HEK 293T cells stably transferring the mitochondrial or nuclear specific expression probe NADS3.0 after Alpha-GPC treatment. (B) Statistical histogram of FRET (RFP/GFP) signal from Alpha-GPC treated HEK 293T cells stably transferring the mitochondrial or nuclear specific expression probe NADS3.0.
Detailed Description
The following detailed description of the present invention will be made in detail to make the above objects, features and advantages of the present invention more apparent, but should not be construed to limit the scope of the present invention.
Example 1: stable transfer of NAD + HEK 293T cell preparation of molecular probe
To detect NAD in cells + The change of the molecular concentration first requires the construction of a stable expression NAD + HEK 293T cells of molecular probes. NAD used + The molecular probes are a probe NADS2.0 based on bioluminescence resonance energy transfer and a probe NADS3.0 based on fluorescence resonance energy transfer. To the two NADs respectively + The N-terminal of the amino acid sequence of the molecular probe is added with a cell nucleus localization peptide sequence (NTS: DPKKKKV) and a mitochondrial localization sequence (MTS: SVLTPLLLRGLTGSARRLPVPRAKIHSL) to obtain Nuc-NADS2.0 (SEQ ID NO. 1), nuc-NADS3.0 (SEQ ID NO. 2) and Mito-NADS2.0 (SEQ ID NO. 3), mito-NADS3.0 (SEQ ID NO. 4) to realize NAD + Cell nucleus and mitochondria specific expression of molecular probes. The encoding genes of the four probes (Nuc-NADS 2.0, nuc-NADS3.0, mito-NADS2.0 and Mito-NADS 3.0) are cloned to a pCDH-CMV-MCS-EF1-Neo vector, and a HEK293 stably transformed cell line is prepared by a lentiviral method.
Probe NADS2.0 consists of green fluorescent protein mNeoGreen, NAD + Binding protein LigA, and bioluminescent protein cpNluc; probe NADS3.0 consists of the red fluorescent protein mScarlet-I, NAD + Binding protein LigA, and green fluorescent protein mNeoGreen (fig. 2). When NAD + The response protein does not bind NAD + When the molecule is in an open state, the probe structure is in an open state, so that the distance between the resonance energy transfer donor and the receptor is long, the resonance energy transfer efficiency is low, and the whole probe emits light of the resonance energy transfer donor. When NAD + Response protein binding NAD + After the molecule, the conformation thereof is changed from an open state to a closed state,the resonance energy transfer donor and the receptor are driven to be close to each other, high resonance energy transfer efficiency is formed, and the probe emits light of the resonance energy transfer receptor. Thus, NAD can be indicated by measuring the intensity of the resonant energy transfer donor and acceptor emission wavelengths within the probe + Concentration level.
Example 2: mito-NADS2.0 and Nuc-NADS2.0 measurement of NAD in cells treated with Alpha-GPC + Horizontal level
HEK 293T cells stably expressing Mito-NADS2.0 or Nuc-NADS2.0 were spread in 96-well white cell culture plates at 10000 cells/well, respectively, and the amount of DMEM medium (containing various amino acids, vitamins, inorganic salts, and high concentration glucose, without phenol red) was 100. Mu.L. At 37 ℃,5% CO 2 After 24h incubation, intracellular NAD was reduced efficiently by using Alpha-GPC (0. Mu.M, 0.1. Mu.M, 0.5. Mu.M, 1. Mu.M, 5. Mu.M, 10. Mu.M) at different final concentrations in FK866 (NAMPT inhibitor) + Level) in the absence or presence (10 nM). After 24h of compound treatment, the DMEM medium (high sugar, no phenol red) was changed to fresh DMEM medium containing bioluminescent substrate (high sugar, no phenol red, bioluminescent substrate diluted 1000-fold). The intensity of the emitted light at 590nm and 440nm wavelengths was detected using a Flex Station3 multifunctional microplate reader. According to the detection principle of the probe, the ratio of the emitted light intensities of 590nm and 440nm wavelengths indicates NAD in living cells + Concentration.
As can be seen from FIG. 3 (A), alpha-GPC at a final concentration of 0.1-10. Mu.M significantly reduced mitochondrial NAD + The content is as follows; the addition of Alpha-GPC at a final concentration of 10. Mu.M also significantly reduced NAD in the presence of 10nM FK866 + Concentration. FIG. 3 (B) shows that Alpha-GPC with a final concentration of 5-10. Mu.M significantly increases nuclear NAD + Level; 1-10. Mu.M Alpha-GPC significantly increased nuclear NAD when treated with 10nM FK866 + Concentration.
Example 3: mito-NADS3.0 and Nuc-NADS3.0 measurement of NAD in cells treated with Alpha-GPC + Horizontal level
HEK 293T cells stably expressing Mito-NADS3.0 or Nuc-NADS3.0, respectively, were expressed at 10 5 Cell amount per mL was spread in cell culture dish with diameter of 35mm, DMEM mediumThe amount of (high sugar, no phenol red) used was 2mL. At 37 ℃,5% CO 2 After 24h incubation under conditions, cells were treated with different final concentrations of Alpha-GPC (0. Mu.M, 5. Mu.M) in the presence of FK866 (10 nM). After 24h of compound treatment, cell NAD was measured using fluorescence microscopy + The content is as follows. The fluorescence microscope parameters were set as follows: excitation wavelength 488nm and emission wavelengths 532nm and 561nm. RFP/GFP light intensity ratios were calculated using imageJ image processing software.
As can be seen from FIG. 4, after treatment with Alpha-GPC at a final concentration of 5. Mu.M, the nuclear FRET signal was significantly increased, while the mitochondrial FRET signal was significantly decreased. This indicates that nuclear NAD + Levels are markedly elevated, while mitochondrial NAD + The concentration is significantly reduced.
SEQUENCE LISTING
<110> Shenzhen advanced technology research institute
<120> use of glycerophosphorylcholine in modulating cellular NAD+ levels and distribution
<130> CP122010315C
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 719
<212> PRT
<213> artificial sequence
<400> 1
Met Asp Pro Lys Lys Lys Arg Lys Val Ala Ser Leu Pro Ala Thr His
1 5 10 15
Glu Leu His Ile Phe Gly Ser Ile Asn Gly Val Asp Phe Asp Met Val
20 25 30
Gly Gln Gly Thr Gly Asn Pro Asn Asp Gly Tyr Glu Glu Leu Asn Leu
35 40 45
Lys Ser Thr Lys Gly Asp Leu Gln Phe Ser Pro Trp Ile Leu Val Pro
50 55 60
His Ile Gly Tyr Gly Phe His Gln Tyr Leu Pro Tyr Pro Asp Gly Met
65 70 75 80
Ser Pro Phe Gln Ala Ala Met Val Asp Gly Ser Gly Tyr Gln Val His
85 90 95
Arg Thr Met Gln Phe Glu Asp Gly Ala Ser Leu Thr Val Asn Tyr Arg
100 105 110
Tyr Thr Tyr Glu Gly Ser His Ile Lys Gly Glu Ala Gln Val Lys Gly
115 120 125
Thr Gly Phe Pro Ala Asp Gly Pro Val Met Thr Asn Ser Leu Thr Ala
130 135 140
Ala Asp Trp Cys Arg Ser Lys Lys Thr Tyr Pro Asn Asp Lys Thr Ile
145 150 155 160
Ile Ser Thr Phe Lys Trp Ser Tyr Thr Thr Gly Asn Gly Lys Arg Tyr
165 170 175
Arg Ser Thr Ala Arg Thr Thr Tyr Thr Phe Ala Lys Pro Met Ala Ala
180 185 190
Asn Tyr Leu Lys Asn Gln Pro Met Tyr Val Phe Arg Lys Thr Glu Leu
195 200 205
Lys His Ser Lys Thr Glu Leu Asn Phe Lys Glu Trp Gln Lys Ala Phe
210 215 220
Thr Asp Lys Leu Thr Leu Thr Ala Ala Thr Thr Arg Ala Gln Glu Leu
225 230 235 240
Arg Lys Gln Leu Asn Gln Tyr Ser His Glu Tyr Tyr Val Lys Asp Gln
245 250 255
Pro Ser Val Glu Asp Tyr Val Tyr Asp Arg Leu Tyr Lys Glu Leu Val
260 265 270
Asp Ile Glu Thr Glu Phe Pro Asp Leu Ile Thr Pro Asp Ser Pro Thr
275 280 285
Gln Asn Val Gly Gly Lys Val Leu Ser Gly Phe Glu Lys Ala Pro His
290 295 300
Asp Ile Pro Met Tyr Ser Leu Asn Asp Gly Phe Ser Lys Glu Asp Ile
305 310 315 320
Phe Ala Phe Asp Glu Arg Val Arg Lys Ala Ile Gly Lys Pro Val Ala
325 330 335
Tyr Cys Cys Glu Leu Leu Ile Asp Gly Leu Ala Ile Ser Leu Arg Tyr
340 345 350
Glu Asn Gly Val Phe Val Arg Gly Ala Thr Arg Gly Asp Gly Thr Val
355 360 365
Gly Glu Asn Ile Thr Glu Asn Leu Arg Thr Val Arg Ser Val Pro Met
370 375 380
Asp Leu Thr Glu Pro Ile Ser Val Glu Val Arg Gly Glu Cys Tyr Met
385 390 395 400
Pro Lys Gln Ser Phe Val Ala Leu Asn Glu Glu Arg Glu Glu Asn Gly
405 410 415
Gln Asp Ile Phe Ala Asn Pro Arg Asn Ala Ala Ala Gly Ser Leu Arg
420 425 430
Gln Leu Asp Thr Lys Ile Val Ala Lys Arg Asn Leu Asn Thr Phe Leu
435 440 445
Tyr Thr Val Ala Asp Phe Gly Pro Met Lys Ala Lys Thr Gln Phe Glu
450 455 460
Ala Leu Glu Glu Leu Ser Ala Ile Gly Phe Arg Thr Asn Pro Glu Arg
465 470 475 480
Gln Leu Cys Gln Ser Ile Asp Glu Val Trp Ala Tyr Ile Glu Glu Tyr
485 490 495
His Glu Lys Arg Ser Thr Leu Pro Tyr Glu Ile Asn Gly Ile Val Ile
500 505 510
Lys Val Asn Glu Phe Ala Leu Gln Asp Glu Leu Gly Phe Thr Val Lys
515 520 525
Ala Pro Arg Trp Ala Ile Ala Tyr Lys Phe Pro Tyr Asp Gln Met Gly
530 535 540
Gln Ile Glu Lys Ile Phe Lys Val Val Tyr Pro Val Asp Asp His His
545 550 555 560
Phe Lys Val Ile Leu His Tyr Gly Thr Leu Val Ile Asp Gly Val Thr
565 570 575
Pro Asn Met Ile Asp Tyr Phe Gly Arg Pro Tyr Glu Gly Ile Ala Val
580 585 590
Phe Asp Gly Lys Lys Ile Thr Val Thr Gly Thr Leu Trp Asn Gly Asn
595 600 605
Lys Ile Ile Asp Glu Arg Leu Ile Asn Pro Asp Gly Ser Leu Leu Phe
610 615 620
Arg Val Thr Ile Asn Gly Val Thr Gly Trp Arg Leu Cys Glu Arg Ile
625 630 635 640
Leu Ala Gly Gly Thr Gly Gly Ser Gly Gly Thr Gly Gly Ser Met Val
645 650 655
Phe Thr Leu Glu Asp Phe Val Gly Asp Trp Arg Gln Thr Ala Gly Tyr
660 665 670
Asn Leu Asp Gln Val Leu Glu Gln Gly Gly Val Ser Ser Leu Phe Gln
675 680 685
Asn Leu Gly Val Ser Val Thr Pro Ile Gln Arg Ile Val Leu Ser Gly
690 695 700
Glu Asn Gly Leu Lys Ile Asp Ile His Val Ile Ile Pro Tyr Glu
705 710 715
<210> 2
<211> 768
<212> PRT
<213> artificial sequence
<400> 2
Met Asp Pro Lys Lys Lys Arg Lys Val Val Ser Lys Gly Glu Ala Val
1 5 10 15
Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Met Asn
20 25 30
Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu
35 40 45
Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro
50 55 60
Phe Ser Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Arg Ala
65 70 75 80
Phe Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Tyr Lys Gln Ser Phe
85 90 95
Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly
100 105 110
Ala Val Thr Val Thr Gln Asp Thr Ser Leu Glu Asp Gly Thr Leu Ile
115 120 125
Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val
130 135 140
Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Thr Glu Arg Leu Tyr
145 150 155 160
Pro Glu Asp Gly Val Leu Lys Gly Asp Ile Lys Met Ala Leu Arg Leu
165 170 175
Lys Asp Gly Gly Arg Tyr Leu Ala Asp Phe Lys Thr Thr Tyr Lys Ala
180 185 190
Lys Lys Pro Val Gln Met Pro Gly Ala Tyr Asn Val Asp Arg Lys Leu
195 200 205
Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Val Val Glu Gln Tyr Glu
210 215 220
Arg Ser Glu Gly Arg His Leu Thr Leu Thr Leu Thr Ala Ala Thr Thr
225 230 235 240
Arg Ala Gln Glu Leu Arg Lys Gln Leu Asn Gln Tyr Ser His Glu Tyr
245 250 255
Tyr Val Lys Asp Gln Pro Ser Val Glu Asp Tyr Val Tyr Asp Arg Leu
260 265 270
Tyr Lys Glu Leu Val Asp Ile Glu Thr Glu Phe Pro Asp Leu Ile Thr
275 280 285
Pro Asp Ser Pro Thr Gln Asn Val Gly Gly Lys Val Leu Ser Gly Phe
290 295 300
Glu Lys Ala Pro His Asp Ile Pro Met Tyr Ser Leu Asn Asp Gly Phe
305 310 315 320
Ser Lys Glu Asp Ile Phe Ala Phe Asp Glu Arg Val Arg Lys Ala Ile
325 330 335
Gly Lys Pro Val Ala Tyr Cys Cys Glu Leu Leu Ile Asp Gly Leu Ala
340 345 350
Ile Ser Leu Arg Tyr Glu Asn Gly Val Phe Val Arg Gly Ala Thr Arg
355 360 365
Gly Asp Gly Thr Val Gly Glu Asn Ile Thr Glu Asn Leu Arg Thr Val
370 375 380
Arg Ser Val Pro Met Asp Leu Thr Glu Pro Ile Ser Val Glu Val Arg
385 390 395 400
Gly Glu Cys Tyr Met Pro Lys Gln Ser Phe Val Ala Leu Asn Glu Glu
405 410 415
Arg Glu Glu Asn Gly Gln Asp Ile Phe Ala Asn Pro Arg Asn Ala Ala
420 425 430
Ala Gly Ser Leu Arg Gln Leu Asp Thr Lys Ile Val Ala Lys Arg Asn
435 440 445
Leu Asn Thr Phe Leu Tyr Thr Val Ala Asp Phe Gly Pro Met Lys Ala
450 455 460
Lys Thr Gln Phe Glu Ala Leu Glu Glu Leu Ser Ala Ile Gly Phe Arg
465 470 475 480
Thr Asn Pro Glu Arg Gln Leu Cys Gln Ser Ile Asp Glu Val Trp Ala
485 490 495
Tyr Ile Glu Glu Tyr His Glu Lys Arg Ser Thr Leu Pro Tyr Glu Ile
500 505 510
Asn Gly Ile Val Ile Lys Val Asn Glu Phe Ala Leu Gln Asp Glu Leu
515 520 525
Gly Phe Thr Val Lys Ala Pro Arg Trp Ala Ile Ala Tyr Lys Phe Gly
530 535 540
Leu Ala Ala Thr His Glu Leu His Ile Phe Gly Ser Ile Asn Gly Val
545 550 555 560
Asp Phe Asp Met Val Gly Gln Gly Thr Gly Asn Pro Asn Asp Gly Tyr
565 570 575
Glu Glu Leu Asn Leu Lys Ser Thr Lys Gly Asp Leu Gln Phe Ser Pro
580 585 590
Trp Ile Leu Val Pro His Ile Gly Tyr Gly Phe His Gln Tyr Leu Pro
595 600 605
Tyr Pro Asp Gly Met Ser Pro Phe Gln Ala Ala Met Val Asp Gly Ser
610 615 620
Gly Tyr Gln Val His Arg Thr Met Gln Phe Glu Asp Gly Ala Ser Leu
625 630 635 640
Thr Val Asn Tyr Arg Tyr Thr Tyr Glu Gly Ser His Ile Lys Gly Glu
645 650 655
Ala Gln Val Lys Gly Thr Gly Phe Pro Ala Asp Gly Pro Val Met Thr
660 665 670
Asn Ser Leu Thr Ala Ala Asp Trp Cys Arg Ser Lys Lys Thr Tyr Pro
675 680 685
Asn Asp Lys Thr Ile Ile Ser Thr Phe Lys Trp Ser Tyr Thr Thr Gly
690 695 700
Asn Gly Lys Arg Tyr Arg Ser Thr Ala Arg Thr Thr Tyr Thr Phe Ala
705 710 715 720
Lys Pro Met Ala Ala Asn Tyr Leu Lys Asn Gln Pro Met Tyr Val Phe
725 730 735
Arg Lys Thr Glu Leu Lys His Ser Lys Thr Glu Leu Asn Phe Lys Glu
740 745 750
Trp Gln Lys Ala Phe Thr Asp Val Met Gly Met Asp Glu Leu Tyr Lys
755 760 765
<210> 3
<211> 739
<212> PRT
<213> artificial sequence
<400> 3
Met Ser Val Leu Thr Pro Leu Leu Leu Arg Gly Leu Thr Gly Ser Ala
1 5 10 15
Arg Arg Leu Pro Val Pro Arg Ala Lys Ile His Ser Leu Ala Ser Leu
20 25 30
Pro Ala Thr His Glu Leu His Ile Phe Gly Ser Ile Asn Gly Val Asp
35 40 45
Phe Asp Met Val Gly Gln Gly Thr Gly Asn Pro Asn Asp Gly Tyr Glu
50 55 60
Glu Leu Asn Leu Lys Ser Thr Lys Gly Asp Leu Gln Phe Ser Pro Trp
65 70 75 80
Ile Leu Val Pro His Ile Gly Tyr Gly Phe His Gln Tyr Leu Pro Tyr
85 90 95
Pro Asp Gly Met Ser Pro Phe Gln Ala Ala Met Val Asp Gly Ser Gly
100 105 110
Tyr Gln Val His Arg Thr Met Gln Phe Glu Asp Gly Ala Ser Leu Thr
115 120 125
Val Asn Tyr Arg Tyr Thr Tyr Glu Gly Ser His Ile Lys Gly Glu Ala
130 135 140
Gln Val Lys Gly Thr Gly Phe Pro Ala Asp Gly Pro Val Met Thr Asn
145 150 155 160
Ser Leu Thr Ala Ala Asp Trp Cys Arg Ser Lys Lys Thr Tyr Pro Asn
165 170 175
Asp Lys Thr Ile Ile Ser Thr Phe Lys Trp Ser Tyr Thr Thr Gly Asn
180 185 190
Gly Lys Arg Tyr Arg Ser Thr Ala Arg Thr Thr Tyr Thr Phe Ala Lys
195 200 205
Pro Met Ala Ala Asn Tyr Leu Lys Asn Gln Pro Met Tyr Val Phe Arg
210 215 220
Lys Thr Glu Leu Lys His Ser Lys Thr Glu Leu Asn Phe Lys Glu Trp
225 230 235 240
Gln Lys Ala Phe Thr Asp Lys Leu Thr Leu Thr Ala Ala Thr Thr Arg
245 250 255
Ala Gln Glu Leu Arg Lys Gln Leu Asn Gln Tyr Ser His Glu Tyr Tyr
260 265 270
Val Lys Asp Gln Pro Ser Val Glu Asp Tyr Val Tyr Asp Arg Leu Tyr
275 280 285
Lys Glu Leu Val Asp Ile Glu Thr Glu Phe Pro Asp Leu Ile Thr Pro
290 295 300
Asp Ser Pro Thr Gln Asn Val Gly Gly Lys Val Leu Ser Gly Phe Glu
305 310 315 320
Lys Ala Pro His Asp Ile Pro Met Tyr Ser Leu Asn Asp Gly Phe Ser
325 330 335
Lys Glu Asp Ile Phe Ala Phe Asp Glu Arg Val Arg Lys Ala Ile Gly
340 345 350
Lys Pro Val Ala Tyr Cys Cys Glu Leu Leu Ile Asp Gly Leu Ala Ile
355 360 365
Ser Leu Arg Tyr Glu Asn Gly Val Phe Val Arg Gly Ala Thr Arg Gly
370 375 380
Asp Gly Thr Val Gly Glu Asn Ile Thr Glu Asn Leu Arg Thr Val Arg
385 390 395 400
Ser Val Pro Met Asp Leu Thr Glu Pro Ile Ser Val Glu Val Arg Gly
405 410 415
Glu Cys Tyr Met Pro Lys Gln Ser Phe Val Ala Leu Asn Glu Glu Arg
420 425 430
Glu Glu Asn Gly Gln Asp Ile Phe Ala Asn Pro Arg Asn Ala Ala Ala
435 440 445
Gly Ser Leu Arg Gln Leu Asp Thr Lys Ile Val Ala Lys Arg Asn Leu
450 455 460
Asn Thr Phe Leu Tyr Thr Val Ala Asp Phe Gly Pro Met Lys Ala Lys
465 470 475 480
Thr Gln Phe Glu Ala Leu Glu Glu Leu Ser Ala Ile Gly Phe Arg Thr
485 490 495
Asn Pro Glu Arg Gln Leu Cys Gln Ser Ile Asp Glu Val Trp Ala Tyr
500 505 510
Ile Glu Glu Tyr His Glu Lys Arg Ser Thr Leu Pro Tyr Glu Ile Asn
515 520 525
Gly Ile Val Ile Lys Val Asn Glu Phe Ala Leu Gln Asp Glu Leu Gly
530 535 540
Phe Thr Val Lys Ala Pro Arg Trp Ala Ile Ala Tyr Lys Phe Pro Tyr
545 550 555 560
Asp Gln Met Gly Gln Ile Glu Lys Ile Phe Lys Val Val Tyr Pro Val
565 570 575
Asp Asp His His Phe Lys Val Ile Leu His Tyr Gly Thr Leu Val Ile
580 585 590
Asp Gly Val Thr Pro Asn Met Ile Asp Tyr Phe Gly Arg Pro Tyr Glu
595 600 605
Gly Ile Ala Val Phe Asp Gly Lys Lys Ile Thr Val Thr Gly Thr Leu
610 615 620
Trp Asn Gly Asn Lys Ile Ile Asp Glu Arg Leu Ile Asn Pro Asp Gly
625 630 635 640
Ser Leu Leu Phe Arg Val Thr Ile Asn Gly Val Thr Gly Trp Arg Leu
645 650 655
Cys Glu Arg Ile Leu Ala Gly Gly Thr Gly Gly Ser Gly Gly Thr Gly
660 665 670
Gly Ser Met Val Phe Thr Leu Glu Asp Phe Val Gly Asp Trp Arg Gln
675 680 685
Thr Ala Gly Tyr Asn Leu Asp Gln Val Leu Glu Gln Gly Gly Val Ser
690 695 700
Ser Leu Phe Gln Asn Leu Gly Val Ser Val Thr Pro Ile Gln Arg Ile
705 710 715 720
Val Leu Ser Gly Glu Asn Gly Leu Lys Ile Asp Ile His Val Ile Ile
725 730 735
Pro Tyr Glu
<210> 4
<211> 788
<212> PRT
<213> artificial sequence
<400> 4
Met Ser Val Leu Thr Pro Leu Leu Leu Arg Gly Leu Thr Gly Ser Ala
1 5 10 15
Arg Arg Leu Pro Val Pro Arg Ala Lys Ile His Ser Leu Val Ser Lys
20 25 30
Gly Glu Ala Val Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu
35 40 45
Gly Ser Met Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly
50 55 60
Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly
65 70 75 80
Gly Pro Leu Pro Phe Ser Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr
85 90 95
Gly Ser Arg Ala Phe Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Tyr
100 105 110
Lys Gln Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe
115 120 125
Glu Asp Gly Gly Ala Val Thr Val Thr Gln Asp Thr Ser Leu Glu Asp
130 135 140
Gly Thr Leu Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro
145 150 155 160
Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Thr
165 170 175
Glu Arg Leu Tyr Pro Glu Asp Gly Val Leu Lys Gly Asp Ile Lys Met
180 185 190
Ala Leu Arg Leu Lys Asp Gly Gly Arg Tyr Leu Ala Asp Phe Lys Thr
195 200 205
Thr Tyr Lys Ala Lys Lys Pro Val Gln Met Pro Gly Ala Tyr Asn Val
210 215 220
Asp Arg Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Val Val
225 230 235 240
Glu Gln Tyr Glu Arg Ser Glu Gly Arg His Leu Thr Leu Thr Leu Thr
245 250 255
Ala Ala Thr Thr Arg Ala Gln Glu Leu Arg Lys Gln Leu Asn Gln Tyr
260 265 270
Ser His Glu Tyr Tyr Val Lys Asp Gln Pro Ser Val Glu Asp Tyr Val
275 280 285
Tyr Asp Arg Leu Tyr Lys Glu Leu Val Asp Ile Glu Thr Glu Phe Pro
290 295 300
Asp Leu Ile Thr Pro Asp Ser Pro Thr Gln Asn Val Gly Gly Lys Val
305 310 315 320
Leu Ser Gly Phe Glu Lys Ala Pro His Asp Ile Pro Met Tyr Ser Leu
325 330 335
Asn Asp Gly Phe Ser Lys Glu Asp Ile Phe Ala Phe Asp Glu Arg Val
340 345 350
Arg Lys Ala Ile Gly Lys Pro Val Ala Tyr Cys Cys Glu Leu Leu Ile
355 360 365
Asp Gly Leu Ala Ile Ser Leu Arg Tyr Glu Asn Gly Val Phe Val Arg
370 375 380
Gly Ala Thr Arg Gly Asp Gly Thr Val Gly Glu Asn Ile Thr Glu Asn
385 390 395 400
Leu Arg Thr Val Arg Ser Val Pro Met Asp Leu Thr Glu Pro Ile Ser
405 410 415
Val Glu Val Arg Gly Glu Cys Tyr Met Pro Lys Gln Ser Phe Val Ala
420 425 430
Leu Asn Glu Glu Arg Glu Glu Asn Gly Gln Asp Ile Phe Ala Asn Pro
435 440 445
Arg Asn Ala Ala Ala Gly Ser Leu Arg Gln Leu Asp Thr Lys Ile Val
450 455 460
Ala Lys Arg Asn Leu Asn Thr Phe Leu Tyr Thr Val Ala Asp Phe Gly
465 470 475 480
Pro Met Lys Ala Lys Thr Gln Phe Glu Ala Leu Glu Glu Leu Ser Ala
485 490 495
Ile Gly Phe Arg Thr Asn Pro Glu Arg Gln Leu Cys Gln Ser Ile Asp
500 505 510
Glu Val Trp Ala Tyr Ile Glu Glu Tyr His Glu Lys Arg Ser Thr Leu
515 520 525
Pro Tyr Glu Ile Asn Gly Ile Val Ile Lys Val Asn Glu Phe Ala Leu
530 535 540
Gln Asp Glu Leu Gly Phe Thr Val Lys Ala Pro Arg Trp Ala Ile Ala
545 550 555 560
Tyr Lys Phe Gly Leu Ala Ala Thr His Glu Leu His Ile Phe Gly Ser
565 570 575
Ile Asn Gly Val Asp Phe Asp Met Val Gly Gln Gly Thr Gly Asn Pro
580 585 590
Asn Asp Gly Tyr Glu Glu Leu Asn Leu Lys Ser Thr Lys Gly Asp Leu
595 600 605
Gln Phe Ser Pro Trp Ile Leu Val Pro His Ile Gly Tyr Gly Phe His
610 615 620
Gln Tyr Leu Pro Tyr Pro Asp Gly Met Ser Pro Phe Gln Ala Ala Met
625 630 635 640
Val Asp Gly Ser Gly Tyr Gln Val His Arg Thr Met Gln Phe Glu Asp
645 650 655
Gly Ala Ser Leu Thr Val Asn Tyr Arg Tyr Thr Tyr Glu Gly Ser His
660 665 670
Ile Lys Gly Glu Ala Gln Val Lys Gly Thr Gly Phe Pro Ala Asp Gly
675 680 685
Pro Val Met Thr Asn Ser Leu Thr Ala Ala Asp Trp Cys Arg Ser Lys
690 695 700
Lys Thr Tyr Pro Asn Asp Lys Thr Ile Ile Ser Thr Phe Lys Trp Ser
705 710 715 720
Tyr Thr Thr Gly Asn Gly Lys Arg Tyr Arg Ser Thr Ala Arg Thr Thr
725 730 735
Tyr Thr Phe Ala Lys Pro Met Ala Ala Asn Tyr Leu Lys Asn Gln Pro
740 745 750
Met Tyr Val Phe Arg Lys Thr Glu Leu Lys His Ser Lys Thr Glu Leu
755 760 765
Asn Phe Lys Glu Trp Gln Lys Ala Phe Thr Asp Val Met Gly Met Asp
770 775 780
Glu Leu Tyr Lys
785

Claims (10)

1. Use of glycerophosphorylcholine for controlling cellular nicotinamide adenine dinucleotide levels and distribution ratios.
2. The use according to claim 1, wherein said glycerophosphorylcholine is used to regulate the level and distribution of nicotinamide adenine dinucleotide in the subcellular structure of living cells;
preferably, the subcellular structure is a nucleus or a mitochondrion.
3. The use according to claim 1, wherein said glycerophosphorylcholine is used to increase nuclear nicotinamide adenine dinucleotide level and profile, and/or to decrease mitochondrial nicotinamide adenine dinucleotide level and profile.
4. Use of glycerophosphorylcholine for the preparation of a pharmaceutical composition for the prevention and/or treatment of diseases associated with the regulation of cellular nicotinamide adenine dinucleotide metabolism.
5. The use according to claim 4, wherein said glycerophosphorylcholine is used for the preparation of a pharmaceutical composition for the prevention and/or treatment of diseases associated with the regulation of the subcellular structure of nicotinamide adenine dinucleotide metabolism.
6. The use according to claim 5, characterized in that said glycerophosphorylcholine is used for the preparation of a pharmaceutical composition for the prevention and/or treatment of diseases associated with a reduced level and distribution of nuclear nicotinamide adenine dinucleotide and/or an elevated level and distribution of mitochondrial nicotinamide adenine dinucleotide;
preferably, the cell nicotinamide adenine dinucleotide metabolism regulation-related disease comprises lipid cell differentiation abnormality, mitochondrial energy metabolism disease, and subcellular NAD expression + Unbalanced distribution of Alzheimer's disease and pseudohypoxia.
7. The application of glycerophosphorylcholine in preparing health products, dietary supplements, functional foods, medical foods or nutritional supplements for regulating and controlling the level and distribution of cell nicotinamide adenine dinucleotide, resisting aging, prolonging the service life of cells, and assisting in reducing blood fat or blood sugar.
8. A pharmaceutical formulation for modulating cellular nicotinamide adenine dinucleotide levels and distribution, wherein the active ingredient of the pharmaceutical formulation comprises glycerophosphorylcholine;
preferably, the pharmaceutical formulation is for increasing nuclear nicotinamide adenine dinucleotide levels and distribution, and/or decreasing mitochondrial nicotinamide adenine dinucleotide levels and distribution.
9. A pharmaceutical composition for preventing and/or treating a disease associated with regulation of cellular nicotinamide adenine dinucleotide metabolism, characterized in that an active ingredient of the pharmaceutical composition comprises glycerophosphorylcholine;
preferably, the pharmaceutical composition is used for preventing and/or treating diseases associated with reduced levels and distribution of nuclear nicotinamide adenine dinucleotide and/or increased levels and distribution of mitochondrial nicotinamide adenine dinucleotide.
10. A health product, dietary supplement, functional food, medical food, or nutritional supplement, characterized in that the ingredients of the health product, dietary supplement, functional food, medical food, or nutritional supplement comprise glycerophosphorylcholine;
preferably, the health product, dietary supplement, functional food, medical food or nutritional supplement is used to regulate cellular nicotinamide adenine dinucleotide level and distribution, to resist aging, to extend cellular life, to assist in reducing blood lipid or to assist in reducing blood glucose.
CN202210425667.0A 2022-04-22 2022-04-22 Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution Pending CN116966191A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210425667.0A CN116966191A (en) 2022-04-22 2022-04-22 Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution
PCT/CN2022/138175 WO2023202099A1 (en) 2022-04-22 2022-12-09 Use of glycerophosphorylcholine in regulating and controlling level and distribution of nad+ in cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210425667.0A CN116966191A (en) 2022-04-22 2022-04-22 Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution

Publications (1)

Publication Number Publication Date
CN116966191A true CN116966191A (en) 2023-10-31

Family

ID=88419030

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210425667.0A Pending CN116966191A (en) 2022-04-22 2022-04-22 Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution

Country Status (2)

Country Link
CN (1) CN116966191A (en)
WO (1) WO2023202099A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1123142B (en) * 1979-09-14 1986-04-30 Lpb Ist Farm USE OF GLYCERYLPHOSPHORIL DERIVATIVES IN THE THERAPY OF DYSLIPEMIA AND HEPATITIS, AND RELATED PHARMACEUTICAL COMPOSITIONS
CN102525992A (en) * 2012-03-09 2012-07-04 徐奎 L-alpha-glycerophosphoryl choline film-coated tablet and preparation method thereof

Also Published As

Publication number Publication date
WO2023202099A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
Mohammadi et al. Study on the interactions of trans-resveratrol and curcumin with bovine α-lactalbumin by spectroscopic analysis and molecular docking
Saihara et al. Pyrroloquinoline quinone, a redox-active o-quinone, stimulates mitochondrial biogenesis by activating the SIRT1/PGC-1α signaling pathway
Ho et al. Nicotinamide nucleotide transhydrogenase (NNT) deficiency dysregulates mitochondrial retrograde signaling and impedes proliferation
Rodgers Heme-based sensors in biological systems
Grosser et al. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome
CN105193777B (en) The synergistic combination of carotenoid and polyphenol
Guerrero-Rubio et al. Betalain health-promoting effects after ingestion in Caenorhabditis elegans are mediated by DAF-16/FOXO and SKN-1/Nrf2 transcription factors
Furuuchi et al. Boysenberry polyphenol inhibits endothelial dysfunction and improves vascular health
Hasselholt et al. Distribution of vitamin C is tissue specific with early saturation of the brain and adrenal glands following differential oral dose regimens in guinea pigs
Nasrollahi et al. A peptide carrier for the delivery of elastin into fibroblast cells
Saha et al. Small molecule inhibitors of arginyltransferase regulate arginylation-dependent protein degradation, cell motility, and angiogenesis
US9308161B2 (en) Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins
Holm et al. Ligand binding induces a sharp decrease in hydrophobicity of folate binding protein assessed by 1-anilinonaphthalene-8-sulphonate which suppresses self-association of the hydrophobic apo-protein
CN111565715A (en) Mitoflavoscin: elimination of Cancer Stem Cells (CSCS) by inhibition of mitochondrial respiration with enzymes containing targeted flavins
Weidinger et al. Oxoglutarate dehydrogenase complex controls glutamate-mediated neuronal death
EP2364698A2 (en) Composition for control of aging and / or extension of life, containing dapsone as active ingredient
Jeevanandam et al. Cytotoxicity analysis of morphologically different sol-gel-synthesized MgO nanoparticles and their in vitro insulin resistance reversal ability in adipose cells
Chen et al. Ultrasmall PtAu2 nanoclusters activate endogenous anti-inflammatory and anti-oxidative systems to prevent inflammatory osteolysis
CN116966191A (en) Glycerol phosphorylcholine regulates cellular NAD + Application in level and distribution
AU2006214489A1 (en) Metabolic-based methods for modulating gene expression
Salazar-Anzures et al. Dietary biotin supplementation increases proliferation pathways in mice testes without affecting serum follicle-stimulating hormone levels and stem cell factor expression
Wu et al. Glut10 restrains neointima formation by promoting SMCs mtDNA demethylation and improving mitochondrial function
Li et al. Identification and anti-oxidative potential of Milk Fat Globule Membrane (MFGM)-derived bioactive peptides released through in vitro gastrointestinal digestion
Nagahawatta et al. Skeletal muscle growth activity of Olive Flounder (Paralichthys olivaceus) meat digest
WO2022210296A1 (en) Oxytocin signal enhancer and oxytocin-induced keratinocyte proliferation-promoting agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination